Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of rPhleum in Rhinoconjunctivitis
NCT01353755Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Oct 2009
- Primary completion
- Aug 2012
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing rPhleum with Placebo (2 arms). Primary endpoint: Rhinoconjunctivitis Symptom-Medication-Score at 2 years. Started Oct 2009; status: completed.
02
Drugs
rPhleum
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01353755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353755.